Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer (Part I Study)

Breast Cancer Clinical Trial

Official title:

An Open-label, Multicentre, Single-arm Safety and Efficacy Clinical Investigation of Diagnostic Microprobe (inPROBE) for the Assessment of HER2 Receptor Expression in Population of Women at High Risk of Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05415943
• Other study ID #: SDS-HER-01-2018
• Status: Completed
• Phase: N/A
• Start date: August 24, 2022
• Est. completion date: March 2, 2023

Study information

• Verified date: July 2023
• Source: SDS Optic S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to preliminarily determine the correlation of HER2 receptor levels detected with the inPROBE diagnostic probe relative to receptor status as determined by standard methods (IHC/FISH), in women with both HER2-positive and HER2-negative breast cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: March 2, 2023
• Est. primary completion date: March 2, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Provision of written informed consent to participate in the clinical investigation;

2. Female patient aged = 18 to = 75 years;

3. The patient's overall health status as determined by Eastern Cooperative Oncology Group (ECOG) from 0 to 1;

4. Preserved full ability to communicate with the investigator and to understand and comply with the requirements of the Clinical investigation plan;

5. High likelihood of attending follow-up appointments in accordance with the study design and completing this study in accordance with this Clinical investigation plan.

6. The presence of a malignant neoplasm (breast cancer) confirmed by histopathologic examination of material from a gross needle biopsy of the tumor, with specific HER2 receptor status.

7. Patient referred for surgical treatment of breast cancer.

Exclusion Criteria:

1. History of treatment with trastuzumab, or other HER 2 receptor-binding antibody, as part of neoadjuvant (induction) therapy for currently diagnosed and treated breast cancer.

2. A skin disorder that prevents or contraindicates to perform a probe examination in the opinion of the investigator;

3. Breast inflammation/infection on the day of the probe examination;

4. Allergy to any component of the medical device that is the subject of this clinical investigation;

5. An implant in the breast where the inPROBE study and surgery will be performed;

6. Any physical or psychiatric condition, or laboratory test values outside the normal range, which in the opinion of the investigator constitute a contraindication to the patient's participation in this clinical investigation or pose a risk of exclusion from the study or premature termination of participation in the study;

7. Any clinically significant abnormality in physical examination, vital signs, or laboratory tests that, in the opinion of the investigator, is a contraindication to participation in this clinical trial;

8. Pregnancy or breastfeeding;

9. Participation in another clinical trial within 30 days prior to signing informed consent to participate in this clinical investigation;

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Device:
• Diagnostic microprobe (inPROBE) medical device
Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.

Locations

Country	Name	City	State
Poland	Uniwersyteckie Centrum Leczenia Chorób Piersi, Szpital Uniwersytecki w Krakowie	Kraków
Poland	Klinika Chirurgii Onkologicznej	Lublin

Sponsors (1)

Lead Sponsor	Collaborator
SDS Optic S.A.

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH).		Day 1
Secondary	The occurrence of defects, failures, and fractures of the inPROBE probe during the diagnostic procedure leading to AE/ SAE.		Day 1 - Day 14
Secondary	Comparison of the correlation of HER2 receptor concentrations detected by the inPROBE probe located in the tumor and in the immediate tumor area in HER2 positive patients.		Day 1